All In Biotech

Drug Trial Radar · NCT07777835

Magnesium Sulphate With Atropine and Pralidoxime vs Standard Therapy Alone in Acute Organophosphate Poisoning

Comparison of the Efficacy of Adjunctive Magnesium Sulphate With Standard Atropine and Pralidoxime Therapy vs Standard Therapy Alone in Acute Organophosphate Poisoning

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

38

Planned (sponsor's estimate)

Start

May 10, 2026

Primary completion

Oct 10, 2026

Study completion Oct 10, 2026

Sponsor

Lead sponsor
Muhammad Aamir LatifAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pakistan, being a developing country, is one of the regions with the most cases of organophosphate (OP) poisoning/toxicity. MgSO4 is one of the most promising adjunctive treatments that needs to be tested. This study is being carried out with the objective of comparing the 15-day all-cause mortality rate and the total cumulative atropine requirement during hospitalization between patients receiving adjunctive magnesium sulphate with standard therapy and those receiving standard therapy alone.

Conditions

  • Organophosphate Poisoning

Interventions

  • Atropine plus pralidoximeDrug

    Patients will be treated with standard atropine and pralidoxime therapy along with adjunctive MgSO4 (loading dose of 4g in 100ml N/S intravenous infusion over 30 minutes, followed by 1g/hr in 100ml N/S continuous IV infusion for 24 hours).

  • Atropine and pralidoxime with adjunctive MgSO4Drug

    Patients will be treated with standard atropine plus pralidoxime therapy alone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: 15 days after hospital admission

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nishtar Hospital/Medical University

    Multan, Punjab Province, Pakistan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.